LL-37: The Human Cathelicidin Antimicrobial Peptide in Research
The human body produces a remarkable arsenal of endogenous defense molecules, and few have attracted as much research attention as the sole cathelicidin-derived antimicrobial peptide found in humans. LL-37, a 37-amino acid peptide cleaved from the precursor protein hCAP18, operates at the intersection of innate immunity, wound healing, and immune modulation. Its multifunctional nature has made it one of the most intensively studied host defense peptides in modern biomedical research.
Structure and Origin
LL-37 is derived from the C-terminal end of the 18 kDa human cationic antimicrobial protein (hCAP18), encoded by the CAMP gene. The precursor protein is cleaved by proteinase 3 in neutrophils to release the mature, active peptide. Its name reflects its structure: it begins with two leucine residues ("LL") and is 37 amino acids in length.
The peptide adopts an amphipathic α-helical conformation in membrane-mimicking environments, with distinct hydrophobic and hydrophilic faces. This structural feature is central to its biological activity, enabling it to interact with negatively charged microbial membranes while sparing host cell membranes to a relative degree. Vandamme et al., 2012 provided a comprehensive review of this structural basis for cathelicidin function.
LL-37 is expressed by a wide variety of cell types, including neutrophils, macrophages, epithelial cells, and keratinocytes. Its expression can be constitutive or induced by inflammatory stimuli, vitamin D signaling, and infection. The vitamin D connection has been particularly well-studied — Liu et al., 2006 demonstrated that toll-like receptor activation in macrophages upregulates LL-37 expression through a vitamin D–dependent pathway, a finding that reshaped understanding of innate immunity against tuberculosis.
Antimicrobial Activity
LL-37 exhibits broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses. Its primary mechanism involves direct disruption of microbial membranes through electrostatic interactions with negatively charged lipopolysaccharides and phospholipids.
Research has demonstrated activity against clinically important pathogens:
Overhage et al., 2008 reported that LL-37 not only kills planktonic P. aeruginosa but also inhibits biofilm formation at concentrations below the minimum inhibitory concentration (MIC). The peptide reduced biofilm formation by >50% at sub-MIC levels and influenced bacterial gene expression patterns related to quorum sensing and motility. This anti-biofilm property is particularly significant given the role of biofilms in chronic and device-related infections.
Beyond membrane disruption, LL-37 can translocate across bacterial membranes and interact with intracellular targets including DNA and RNA, as described by Hale & Hancock, 2007. This multi-target mechanism may help explain why bacteria have difficulty developing resistance to host defense peptides compared to conventional antibiotics.
Immunomodulatory Functions
Perhaps more intriguing than its direct antimicrobial activity is LL-37's role as an immune modulator. The peptide functions as a signaling molecule that bridges innate and adaptive immunity through multiple pathways.
Key immunomodulatory activities identified in research include:
Scott et al., 2002 demonstrated that LL-37 selectively modulates macrophage responses to bacterial components, suppressing TNF-α and nitric oxide production induced by LPS while enhancing the expression of chemokines that recruit immune cells. This nuanced modulation suggests the peptide helps orchestrate an effective immune response while limiting excessive inflammation.
Lande et al., 2007 showed that LL-37 can form complexes with self-DNA fragments, converting them into potent activators of plasmacytoid dendritic cells through TLR9 signaling. This finding has significant implications for understanding autoimmune conditions, particularly psoriasis, where LL-37 is overexpressed in skin lesions.
Wound Healing Research
LL-37 has been studied extensively for its roles in tissue repair and regeneration. The peptide promotes wound healing through several complementary mechanisms that go beyond infection prevention.
Research by Koczulla et al., 2003 demonstrated that LL-37 stimulates angiogenesis — the formation of new blood vessels — through activation of FPRL1 on endothelial cells. This neovascularization is critical for delivering nutrients and immune cells to wound sites.
Additional wound healing mechanisms under investigation include:
Heilborn et al., 2003 found that LL-37 is significantly upregulated in acute wound fluid but notably absent in chronic, non-healing ulcers. This observation suggests a potential role for LL-37 deficiency in impaired wound healing and has motivated research into exogenous LL-37 application for chronic wound models.
Role in Disease States
The relationship between LL-37 and disease is complex and bidirectional. Deficiency and overexpression are both associated with pathological states.
Deficiency-associated conditions:
Overexpression-associated conditions:
Yamasaki et al., 2007 elucidated the mechanism in rosacea, showing that abnormal cathelicidin processing generates proinflammatory peptide fragments distinct from LL-37 that promote vascular changes and inflammation characteristic of the disease. This work fundamentally shifted the understanding of rosacea from a purely vascular condition to one involving innate immune dysfunction.
Anti-Cancer Research
Emerging research has explored LL-37's effects on cancer cells, though findings are notably context-dependent. Kuroda et al., 2015 observed that LL-37 can induce apoptosis in certain cancer cell lines, including gastric and oral squamous cell carcinomas, through mitochondrial membrane depolarization.
However, the picture is not uniformly promising. Some studies have found that LL-37 can promote tumor growth in ovarian cancer and lung cancer models by activating proliferative signaling pathways. Coffelt et al., 2008 reported that LL-37 promoted ovarian cancer cell proliferation through FPRL1-mediated activation of the EGFR-HER2 signaling cascade. This dual nature underscores the need for careful, context-specific research.
Current Research Challenges
Despite its promise, translating LL-37 research faces notable hurdles:
Researchers are addressing these challenges through the development of truncated analogs, D-amino acid substitutions, and delivery systems including nanoparticle encapsulation. Nell et al., 2006 developed P60.4Ac, a truncated LL-37 derivative with improved stability and comparable antimicrobial activity, which has progressed into clinical-stage development for topical applications.